FIELD: biotechnology.
SUBSTANCE: fusion protein for treating or preventing a disease caused by a pathogen or tumor in a subject is provided. The fusion protein includes an immunogenic polypeptide of interest, a transmembrane domain, and an HIV gag polypeptide or functionally equivalent variants thereof. The invention also relates to a polynucleotide, expression vector, host cell and virus-like particle expressing or presenting the said fusion protein. Besides, pharmaceutical and immunogenic compositions containing fusion proteins, polynucleotides, vectors or virus-like particles of the invention, as well as their use in human and veterinary medicine are disclosed.
EFFECT: invention ensures the formation of virus-like particles with high and specific immunogenicity.
22 cl, 24 dwg, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DERIVATIVES OF PROTEIN FUSED WITH Fc WITH HIGH DOUBLE ACTIVITY: ANTIVIRAL ACTIVITY RELATIVELY TO HIV AND IMMUNOMODULATING ACTIVITY | 2018 |
|
RU2774782C2 |
| IMMUNOGENS FOR VACCINATION AGAINST HIV | 2013 |
|
RU2721274C2 |
| GENE THERAPY OF HYPOPHOSPHATEMIC DISEASES ASSOCIATED WITH FIBROBLAST GROWTH FACTOR 23 | 2020 |
|
RU2815545C2 |
| HERPES VACCINE | 2019 |
|
RU2731073C1 |
| RSV F MUTANT PROTEIN AND ITS APPLICATION | 2020 |
|
RU2807742C1 |
| POLYVALENT AND POLYSPECIFIC GITR-BINDING FUSED PROTEINS | 2016 |
|
RU2753439C2 |
| IMMUNO-INDUCING AGENT | 2016 |
|
RU2744843C2 |
| MULTIVALENT PD-L1-BINDING COMPOUNDS FOR TREATING MALIGNANT NEOPLASMS | 2020 |
|
RU2816646C2 |
| CHIMERIC PROTEINS BASED ON TIGIT AND LIGHT | 2018 |
|
RU2775490C2 |
| POLYPEPTIDES THAT ARE SOLUBLE RECEPTORS OF FIBROBLAST GROWTH FACTOR 3 (sFGFR3), AND WAYS OF THEIR APPLICATION | 2017 |
|
RU2751483C2 |
